Quantum BioPharma Advances Lucid-MS Toward Phase 2 in MS
NEW YORK — September 11, 2026 Quantum BioPharma Ltd. announced that the U.S. Food and Drug Administration has cleared...
Phase 2
Advertisement
Disc Medicine Advances DISC-3405 in Polycythemia Vera
WATERTOWN, Mass. — September 9, 2026 Disc Medicine, Inc. presented positive initial results from the Phase 2 RESTORE-PV trial...
Beeline Medicines Advances Afimetoran Toward Pivotal Lupus Trials
STAMFORD, Conn. — September 9, 2026 Beeline Medicines Corporation announced positive topline results from its global Phase 2 study...
Fate Therapeutics Presents FT819 Clinical Data at CCR-West 2026
SAN DIEGO — September 9, 2026 Fate Therapeutics, Inc. announced that new clinical data for its off-the-shelf anti-CD19 CAR...
Leyden Labs Advances RIG-101 Toward Phase 2 in Asthma
LEIDEN, Netherlands — September 9, 2026 Leyden Laboratories B.V. announced positive Phase 1 results for RIG-101, supporting advancement of...
Advertisements
Revvity to Acquire Human Cell Design for Metabolic Drug Discovery
WALTHAM, Mass. — September 9, 2026 Revvity, Inc. announced that it has entered into a definitive agreement to acquire...
Quoin Pharmaceuticals Gains FDA Pediatric Designation for QRX003
ASHBURN, Va. — September 8, 2026 Quoin Pharmaceuticals Ltd. announced that the U.S. Food and Drug Administration (FDA) has...
Spyre Therapeutics Advances SPY003 in UC with Positive Phase 2 Data
WALTHAM, Mass. — September 8, 2026 Spyre Therapeutics announced positive 12-week induction results from Part A of the Phase...
BioAge Labs Begins Phase 2 Trial of Oral BGE-102
EMERYVILLE, California — September 8, 2026 BioAge Labs announced that the first participant has been dosed in the Phase...
Verastem Oncology Advances VS-7375 Across KRAS G12D Cancers
BOSTON, Massachusetts — September 8, 2026 Verastem Oncology announced plans to host an investor event and webcast on October...
Advertisement
